Organogenesis (NASDAQ:ORGO) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen cut shares of Organogenesis (NASDAQ:ORGO) from a sell rating to a strong sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Several other research firms have also recently weighed in on ORGO. Truist Financial reduced their target price on shares of Organogenesis from $3.00 to $2.00 and set a “hold” rating for the company in a research note on Friday, August 7th. Weiss Ratings lowered Organogenesis from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, October 19th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $4.33.

Organogenesis Price Performance

Shares of Organogenesis stock opened at $0.81 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.52 and a quick ratio of 3.00. Organogenesis has a fifty-two week low of $0.73 and a fifty-two week high of $7.08. The firm has a fifty day moving average price of $1.26 and a two-hundred day moving average price of $2.31. The company has a market cap of $104.64 million, a PE ratio of -0.67 and a beta of 1.48.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). Organogenesis had a negative return on equity of 48.62% and a negative net margin of 39.34%. The company had revenue of $45.46 million for the quarter, compared to the consensus estimate of $52.10 million.

Institutional Trading of Organogenesis

Several institutional investors have recently bought and sold shares of ORGO. Waverly Advisors LLC bought a new stake in Organogenesis in the second quarter valued at $25,000. Sequoia Financial Advisors LLC bought a new position in shares of Organogenesis during the second quarter valued at $33,000. Pallas Capital Advisors LLC bought a new position in shares of Organogenesis during the second quarter valued at $37,000. The Manufacturers Life Insurance Company bought a new position in shares of Organogenesis during the second quarter valued at $44,000. Finally, Capital Square LLC acquired a new stake in shares of Organogenesis in the 2nd quarter valued at $45,000. Institutional investors and hedge funds own 49.57% of the company’s stock.

Key Stories Impacting Organogenesis

Here are the key news stories impacting Organogenesis this week:

• Positive Sentiment: Management expects to reduce annual operating expenses by approximately $45 million, which could help lower costs. Third-quarter net product revenue also rose 6% from the prior quarter, signaling some sequential recovery. Article: Organogenesis: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: The earnings call was characterized as showing signs of recovery alongside major setbacks; the sequential revenue improvement and cost-cutting plan offer possible offsets, but do not erase the weak quarterly results. Article: Organogenesis Earnings Call Signals Recovery Amid Major Setbacks
• Negative Sentiment: Organogenesis reported a third-quarter loss of $0.25 per share, wider than the $0.18 loss analysts expected. Revenue of $45.46 million also missed the $52.10 million consensus estimate, raising concerns about near-term performance. Article: Organogenesis Reports Third Quarter 2026 Financial Results

About Organogenesis

Organogenesis Holdings Inc is a biotechnology company that develops, manufactures and commercializes products intended to support tissue regeneration and wound healing. The company serves the advanced wound care and surgical and sports medicine markets, with a focus on therapies that help manage complex wounds and support the repair of damaged tissue.

Its product portfolio includes bioengineered skin substitutes and other biologic products, such as Apligraf, Dermagraft, NuShield, Affinity and NuCel.